Examples of 'bcr-abl' in a sentence
Meaning of "bcr-abl"
bcr-abl: referring to a specific genetic mutation associated with certain types of leukemia
How to use "bcr-abl" in a sentence
Basic
Advanced
bcr-abl
Discovery and development of Bcr-Abl tyrosine kinase inhibitors.
Ponatinib acts by blocking a tyrosine kinase called Bcr-Abl.
The transcriptional targets of Bcr-Abl in leukemic cells have not been extensively studied.
Dasatinib inhibits the action of the Bcr-Abl protein.
Transcription through the bcr-abl translocation results in the generation of fusión mRNAs.
Dasatinib acts mainly by blocking the Bcr-Abl protein kinase.
The chimeric protein of bcr-abl translocation has tirosino-kinase activity increased and abnormal.
The latter encodes the oncogenic Bcr-Abl fusión protein.
Modeling studies indicate that bosutinib binds the kinase domain of Bcr-Abl.
Liposomal-antisense oligonucleotides targeted to bcr-abl can reduce proliferation of CIvIL cells.
Bcr-Abl is the underlying cause of chronic myeloid leukemia.
Nilotinib acts by blocking the protein kinase called Bcr-Abl kinase.
Soon after identification of the bcr-abl target, the search for an inhibitor began.
Tasigna was designed to be a more potent and selective inhibitor of Bcr-Abl and its mutations.
In particular embodiments, the Bcr-Abl inhibitor is selected from the group of imatinib and nilotinib.
See also
Although employed in other indications, Gleevec is most effective targeting BCR-Abl.
The band intensity of the bcr-abl kinase was quantified by Densitometric analysis.
Drug resistance is the main drive in continuing research and development of Bcr-Abl TKI.
The Bcr-Abl tyrosine kinase acts upstream of the KSP protein.
Bosutinib inhibits the abnormal Bcr-Abl kinase that promotes CML.
By blocking Bcr-Abl kinase, Tasigna helps to control the spread of leukaemia cells.
Dasatinib is a multi targeted inhibitor of Bcr-Abl and Src family kinases.
Cancers with Bcr-Abl oncogenic transformations that clearly require activation of JNK are also included.
FISH is a quantitative test that can identify the presence of the Bcr-Abl gene.
BCR-Abl is then capable of transforming B-cells through the increase of mitogenic activity.
Furthermore, CML is often characterized as containing the BCR-Abl translocation which is absent in AML.
The bcr-Abl fusión protein does not include the regulatory myristolylation site B.
Individual probes hybridize to distinct bcr-abl junction species associated with CML and ALL.
BCR-Abl is then capable of transfoming B-cells through the increase of mitogenic activity.
Test for activity against Bcr-Abl.
This oncogene encodes the bcr-abl tyrosine kinase ( tk ) which presents a constitutive activity.
In some embodiments, the second compound is a Bcr-Abl inhibitor.
This chromosome produces an enzyme, called Bcr-Abl kinase, that leads to the development of leukaemia.
In some embodiments, the tyrosine kinase inhibitor is an inhibitor of BCR-Abl.
Imatinib works by stopping the Bcr-Abl tyrosine-kinase.
In some examples, the tyrosine kinase inhibitor is an inhibitor of BCR-Abl.
Chronic myeloid leukemia, characterized by the bcr-abl fusion gene, still poses challenges to patient treatment.
It functioned as a typically ATP-competitive inhibitor, superior to other existing Bcr-Abl inhibitors.
Mutations in the Bcr-Abl tyrosine kinase can confer resistance to Glivec ®.
This cell line is characterized by a b2a2 breakpoint bcr-abl fusión protein.
Several Bcr-Abl cleavage products are noted in the primary CML samples as reported90.
Providing a sample containing a first single-stranded fusión nucleic acid comprising a bcr-abl splice junction ;.
A non-limiting example of a Bcr-Abl and Src tyrosine-kinase inhibitor is dasatinib.
Here, we investigated the laao from calloselasma rhodostoma ( cr-laao ) antitumoral potential against bcr-abl positive cells.
Examples of small molecule inhibitors of Bcr-Abl include but are not limited to ponatinib ( Iclusig ® ).
In a further embodiment, the compound interacts with Bcr-abl.
Bcr-Abl and mutations of this kinase are the cause of chronic myelogenous leukemia ( CML ).
In another further embodiment, the compound targets the binding site of Bcr-abl.
Bcr-Abl codes for a tyrosine kinase, which is constitutively active, leading to uncontrolled cell proliferation.
Concordantly, STAT5-phosphorylation rapidly decreased in the presence of the Bcr-Abl inhibitor Gleevec.
